PRZOOM - /newswire/ -
Amherst, NH, United States, 2010/04/14 - Greystone Associates analyzes the Therapeutic demand and Treatment Options for Orthopedic joint disease as Patient Populations Continue to Age.
The administration of therapeutic drugs directly into the joint is an accepted method for providing temporary relief to orthopedic patients for periods that range from a few hours to several months. The associated discomfort and the therapeutic approaches to joint disease vary based on the underlying pathology, and include viscous fluid injections for osteoarthritis, glucocorticoids to reduce inflammation, immune factors for autoimmune forms of arthritis, injectable bone substitutes and growth factors, as well as autologous treatments which currently focus on treating damaged and diseased cartilage. These treatments, and the companies behind them, are working to address an underserved market need that is likely to rank among the top ten healthcare growth sectors by 2015.
The aging of populations, particularly in developed economies where active lifestyles are prominent, the growth in the incidence of autoimmune diseases, and the increase in obesity and related metabolic diseases in western countries are converging to drive the growth in the occurrence of orthopedic joint conditions and present a favorable outlook for market sector participants. While the recent market focus has been on establishing optimized protocols and extending the efficacy period for established product segments such as the glucocorticoids and viscosupplements, several players are working to establish the use of other classes of therapeutic injectables such as growth factors, immune modulators, and stem cells, as viable treatment options.
While glucocorticoids work by downregulating inflammation, viscosupplements achieve their therapeutic effect by replacing the joint’s natural viscous fluid layer, cushioning the union between two surfaces. The therapeutic potential of the newer classes of intra-articular injectables are based on their ability to act on specific growth factors and receptors to upregulate the body’s natural healing process.
A new report analyzes the current market and future potential for intra-articular injectables. The report examines existing markets for therapeutic injectables and provides forecasts through 2013. Assessments of key market segments, technology factors, demand drivers and the competitive landscape are also provided.
More information is available at greystoneassociates.org
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis. Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.